BioConnection, ChemConnection, and Proxy announce successful release of the first 'Combidex' batch for the Radboudumc, Nijmegen, the Netherlands

Pivot Park, Oss, The Netherlands, February 18, 2014

BioConnection, ChemConnection and PROXY are honored to announce the successful release of the first batch of Combidex, a revolutionary product from the Radboudumc Department of Radiology and Nuclear Medicine initiated by Professor Jelle Barentsz. This achievement was made under the lead and management of BioConnection. ChemConnection manufactured the API batch and PROXY, a wholly owned subsidiary of Sinenis LifeSciences, performed the formulation and product release.

Press release BioConnection February 18th 2014

The product is an important step forward in lymph node imaging enabling better cancer treatment. The cooperation shows the innovative power of the Dutch life sciences industry and University and combines state of the art chemistry, analytics and GMP manufacturing of high-tech nano-suspensions.

Professor Jelle Barentsz of the Radboudumc: "It was a great experience working with these high-tech Dutch companies. They were able to meet tight timelines and developed and manufactured this high-tech product beyond expectation. They succeeded where others failed. This product will open better ways for diagnostics of prostate- and other cancer. The cooperation of the three companies was unique, last but not least a result of the management by BioConnection, and the final result is fantastic".

Dr. Alexander Willemse, CEO of BioConnection, also on behalf of Dr. Gerjan Kemperman, CEO of ChemConnection, and Dr. Ruud Santing, CEO of Sinensis LifeSciences : 'The enthusiasm of Professor Jelle Barentsz pushed us forward. He was a good source of inspiration. The chemistry and analytics of this product are highly complex but by joining forces we were able to successfully develop and manufacture this product. It was a challenge for chemistry, analytics and fill & finish. We are very proud that we were able to release our first batch for human use and contribute to this breakthrough in cancer therapy'.

BioConnection ( is a Dutch contract services and manufacturing organization for the development and production of injectable (bio)pharmaceutical products. We have access to various GMP manufacturing facilities across Europe that are all in compliance with the guidelines issued by EMA and/or the US-FDA. The cornerstones of our CMC services are: Drug Product development (formulation, analytics, freeze-dry cycle), fill & finish and freeze-drying at clinical and commercial scale. We are currently expanding our capabilities with the development and GMP manufacturing of complex formulations such as microspheres, liposomes and nanoparticles.

We have the means and expertise to bring your invention from the lab bench to the clinic and/or to the market. Due to our unique setup and best-in-class European network of development and manufacturing partners we are able to provide you with tailor made solutions with unmatched flexibility. Our approach ensures a seamless development and manufacturing chain for your product.

If you want to experience what BioConnection can offer for your development or manufacturing project, please contact us.


Contact for BioConnection:

Sjaak Stevense MD - Director Business Development

Tel. +31-412637937 - This email address is being protected from spambots. You need JavaScript enabled to view it.


Contact for Radboud University:

Prof. Dr. J. Barentsz

Radboud University Nijmegen Medical Centre - Department of Radiology

This email address is being protected from spambots. You need JavaScript enabled to view it.